Abstract
With the development of tumor immunological theory and technology, the treatment of blood malignancies is in a new era. Adoptive cellular immunotherapy (ACI) has become the hotspot of researches. Chimeric antigen receptor (CAR) modified T cell shows prominent therapeutic effect in various trails treating blood malignancies. In this paper, we describe the construction of CAR-T cell, choice of targets, clinical experiments related to CAR-T cell therapy in recent years, and the problems remain to be solved. Key words: Receptors, antigen; Hematologic neoplasms; Cellular immunotherapy, adoptive
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
